Group 1 - The Hong Kong medical sector continues to lead the market, with significant gains in innovative drugs and vaccines, as evidenced by the Hong Kong Medical ETF Fuqun (159506) rising by 3.48% [1] - Notable individual stocks such as 3SBio, InnoCare Pharma, and BeiGene have seen increases exceeding 6% [1] - The completion of negotiations for the 2025 National Basic Medical Insurance Drug List and commercial insurance innovative drug pricing has involved 120 domestic and foreign enterprises, with 127 drugs participating in the basic medical insurance negotiations and 24 in commercial insurance [1] Group 2 - The Hong Kong Medical ETF Fuqun (159506) closely tracks the Hang Seng Hong Kong Stock Connect Healthcare Index (HSSCHI), with a focus on companies with high R&D spending and innovative drug business [2] - Companies with the lowest average R&D/income rankings over the past two years are removed from the index, ensuring a focus on innovation [2] - This index structure aids investors in accurately capturing investment opportunities within the Hong Kong pharmaceutical sector [2]
港股医药重回市场焦点！港股通医疗ETF富国（159506）盘中涨幅达3.48%
Mei Ri Jing Ji Xin Wen·2025-11-13 03:26